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 Objective To investigate the pattern of malignancies in Chinese patients 
with neuroﬁbromatosis type 1.
 Design Historical cohort study.
 Setting Queen Mary Hospital and Duchess of Kent Children’s Hospital 
in Hong Kong.
 Patients Patients with neuroﬁbromatosis type 1 seen between January 
1995 and August 2011.
 Results We identiﬁed 123 Chinese patients with neuroﬁbromatosis type 
1, diagnosed at a median age of 4.9 years (range, 0.1-16.1 years); 
75 (61%) were males. They were followed up for a median of 
9.7 years (range, 0.2-27.6 years). Most (80%) of the patients 
participated in our surveillance programme. Twelve patients 
developed malignancies at the ages of 0.8 to 41.6 years. These 
malignancies included: peripheral nerve sheath tumours (n=3), 
juvenile myelomonocytic leukaemia (n=2), optic nerve glioma 
(n=1), thalamic pilocytic astrocytoma (n=1), rhabdomyosarcoma 
(n=1), osteosarcoma (n=1), neuroblastoma (n=1), anaplastic large 
cell lymphoma (n=1), and breast carcinoma and subsequently 
carcinoma of the ampulla of Vater (n=1). Among them, three 
had their tumours (optic glioma, thalamic astrocytoma, sacral 
malignant peripheral nerve sheath tumour) initially detected 
by surveillance imaging. Four patients survived without disease 
progression, three are alive with active disease, the remaining 
ﬁve died (when aged 3 to 56 years) with progressive or relapsed 
malignancies. The latter patients died from a neuroblastoma, 
a juvenile myelomonocytic leukaemia, a malignant peripheral 
nerve sheath tumour, a lymphoma, and a second primary 
tumour (carcinoma of ampulla of Vater, at the age of 56 years). 
In neuroﬁbromatosis type 1 patients with malignancy, overall 
30-year survival was signiﬁcantly shorter than in those without 
malignancy (35% vs 93%, P<0.001). 
 Conclusion Chinese patients with neuroﬁbromatosis type 1 are susceptible 
to different malignancies which contribute to mortality. These 
ﬁndings are similar to reports from overseas. Outcomes were 
unfavourable, except in patients having low-grade gliomas. 
Surveillance imaging may help early detection of deep-seated 
malignancies but the beneﬁts accruing from such monitoring 
warrants prospective evaluation.
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Introduction
Neuroﬁbromatosis type 1 (NF1), also known as von Recklinghausen’s disease, is a genetic 
disorder due to mutations in the NF1 gene which is located in chromosome 17q11.2. 
New knowledge added by this study
• This is the ﬁrst cohort study on Chinese patients with neuroﬁbromatosis type 1 (NF1) and 
malignancies. 
• A diversity of malignancies at different ages was found.
• Malignancies accounted for most of the mortality in these patients; signiﬁcantly reduced 
survival was also found in them.
Implications for clinical practice or policy
• Chinese patients with NF1 should be monitored for the development of malignancies.
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About half of the cases are inherited in an autosomal 
dominant manner and the rest are caused by de-novo 
mutations.1 The mutation affects approximately 1 in 
3000 to 3500 individuals,2,3 with approximately equal 
gender distribution,4-6 has complete penetrance 
but variable expressivity. It is diagnosed when two 
of the following seven National Institutes of Health 
(NIH) criteria7 are present: (1) more than six café 
au lait macules exceeding a diameter of 0.5 cm (in 
prepubertal individuals) or 1.5 cm (in those who 
are post-pubertal); (2) axillary or inguinal freckles; 
(3) two or more neuroﬁbromas or one plexiform 
neuroﬁbroma; (4) two or more Lisch nodules in 
the iris; (5) an optic glioma; (6) sphenoid dysplasia 
or thinning of long bone cortex with or without 
pseudarthrosis; and (7) conﬁrmed NF1 in a ﬁrst-
degree relative. Many of these manifestations may 
not be present at birth and hence only about half 
of the patients are diagnosed in infancy.8 Many 
NF1 patients suffer from a myriad of morbidities in 
addition to those stipulated in the diagnostic criteria. 
These include growth disturbances, developmental 
impairments and learning disabilities, seizures, 
scoliosis, osteoporosis, vasculopathy, hypertension, 
and various malignancies.9 
 The clinical manifestations of NF1 are caused 
by the loss of functional neuroﬁbromin protein 
encoded by the NF1 gene. Neuroﬁbromin is a 
GTPase-activating protein that down-regulates the 
proto-oncogene p21,10 which activates a number 
of signalling pathways promoting cell growth and 
proliferation. Loss or hypofunction of neuroﬁbromin 
favours uncontrolled cellular proliferation and 
oncogenesis. Thus, NF1 is considered a tumour 
suppressor gene, as loss or hypofunction of one copy 
in the germline predisposes individuals to develop 
malignancies. Brain tumours are the most common 
neoplasms in patients with NF1, and affect up to 15 to 
20% of patients11,12; optic pathway low-grade glioma 
constitutes the largest proportion.5,13-15 Although not 
considered malignancies in the pathological sense, 
these tumours can cause considerable morbidity or 
even mortality, and may warrant intensive treatment 
involving surgery, chemotherapy, or radiotherapy. 
Malignant peripheral nerve sheath tumour (MPNST) 
is one of the most common extracranial malignancies 
associated with NF1, and has been reported in about 
5 to 15% of patients.13,16-18
 In our paediatric unit in the Hong Kong West 
Cluster of the Hospital Authority, we have followed 
NF1 patients over several decades. We have also 
accepted referrals from other doctors in Hong Kong, 
as well as Macau, mainland China, and Southeast 
Asia. A neuroﬁbromatosis surveillance programme 
was set up in the Duchess of Kent Children’s Hospital 
in 1997 to provide regular surveillance examinations 
and investigations to identify and manage co-
morbidities. We therefore set out to review the 
 目的 研究一型神經纖維瘤的華籍患者中惡性病變的模式。
 設計 歷史隊列研究。
 安排 香港瑪麗醫院及根德公爵夫人兒童醫院。
 患者 1995年1月至2011年8月期間患有一型神經纖維瘤的
病人。
 結果 共有123名一型神經纖維瘤的華籍患者，其中75人
（61%）為男性；確診年齡中位數為4.9歲（介乎0.1
至16.1歲）；追蹤期中位數為9.7年（介乎0.2至27.6
年）。大部份患者（80%）參與醫院的監察計劃。12
人在0.8至41.6歲的時候發現惡性病變。惡性病變包括
外周神經鞘瘤（3例）、幼年單核細胞白血病（2例）
、視神經膠質瘤（1例）、丘腦毛細胞型星形細胞瘤
（1例）、橫紋肌肉瘤（1例）、骨肉瘤（1例）、神
經母細胞瘤（1例）、間變性大細胞淋巴瘤（1例）、
以及乳腺癌和及後的乏特氏壺腹腺癌（1例）。當中
3例在監察計劃的成像過程中被發現（視神經膠質
瘤、丘腦毛細胞型星形細胞瘤、骶骨惡性外周神經鞘 
瘤），4例病情並無惡化及仍然生存，3例病情惡化
但仍生存。餘下的5例因病情惡化或復發而死亡，其
惡性病變包括神經母細胞瘤、幼年單核細胞白血病、
惡性外周神經鞘瘤及淋巴瘤（患者死亡年齡介乎3至
56歲），另1例為二重癌（乏特氏壺腹腺癌，患者死
亡年齡56歲）。與沒有惡性病變的患者比較，患有惡
性病變的一型神經纖維瘤患者的30年生存率明顯較低
（93%比35%；P<0.001）。
 結論 一型神經纖維瘤的華籍患者較容易出現不同的惡性病
變而引致死亡。這現象與其他國家的情況相似。除了
患有低惡性度膠質瘤的病人外，所有患者的治療結果
並不理想。醫院的監察計劃可能有助及早發現深部腫
瘤，但類似的監察計劃是否真的可以為病人帶來好處
仍需進一步長遠的評估。
一型神經纖維瘤的華籍患者的惡性病變
pattern of malignancies in these patients, and their 
management and outcomes.
Methods
Study design and participants
This was a retrospective review of all Chinese patients 
with conﬁrmed NF1 seen in the Hong Kong West 
Cluster (Queen Mary Hospital and Duchess of Kent 
Children’s Hospital), a university-afﬁliated tertiary 
referral centre in Hong Kong, over the past 16 years 
(January 1995 to August 2011). Patients were identiﬁed 
by electronic search of the Clinical Data Analysis 
and Reporting System (CDARS) of the Hospital 
Authority, using the ICD10 diagnostic codes of 273.70 
(neuroﬁbromatosis) and 273.71 (neuroﬁbromatosis 
type 1). We also searched the electronic clinical 
    Cheuk et al 
44 Hong Kong Med J  Vol 19 No 1  February 2013   www.hkmj.org
database of the Paediatric Haematology/Oncology 
Division of Queen Mary Hospital, which has 
registered all children with haematological and 
oncological diseases since 1991. 
 Our department has started to manage and 
follow-up patients with NF1 well before 1995. 
However, the current electronic database in the 
Hospital Authority could only retrieve patients 
registered on or after 1995. In 1997, a more structured 
NF1 surveillance programme was initiated in the 
Duchess of Kent Children’s Hospital to provide 
regular surveillance examinations and investigations 
to identify and manage co-morbidities. The 
components of the surveillance programme are 
shown in Table 1. Patients with NF1 were mainly seen 
at the Duchess of Kent Children’s Hospital. Patients 
with complicated neuroﬁbromas or suspected 
malignancies were also seen at the Haematology or 
Oncology Clinics in Queen Mary Hospital. In general, 
patients were referred to adult medical services after 
they reached adulthood (18 years old).
 Patient data on demographic and clinical 
characteristics were extracted from the computerised 
Clinical Management System and the clinical 
database of the Haematology/Oncology Division 
of our department. Patients who fulﬁlled the NIH 
diagnostic criteria of NF1 were included, and those 
who had isolated features only (such as café au lait 
macules) were excluded. Patients who were not 
ethnic Chinese were also excluded. In this review, all 
malignant neoplasms and brain tumours (high- and 
low-grade) were included as ‘malignancies’. 
Statistical analyses
The cumulative frequency of malignancy in NF1 
patients at different time points was estimated by the 
Kaplan-Meier method. Overall survival and event-free 
survival of NF1 patients with malignancy were also 
estimated by the Kaplan-Meier method. The overall 
survival of NF1 patients with and without malignancy 
was compared by the log rank test. A  two-tailed P 
value of <0.05 was considered statistically signiﬁcant.
Results
We identiﬁed 123 Chinese patients with conﬁrmed 
NF1. Of these, 57 were identiﬁed from both the 
CDARS of Hospital Authority and the database of 
the Paediatric Haematology/Oncology Division of 
Queen Mary Hospital, 63 only from the CDARS of 
the Hospital Authority, and 3 only from the database 
of the Paediatric Haematology/Oncology Division 
of Queen Mary Hospital. They were diagnosed at a 
median age of 4.9 years (range, 0.1-16.1 years); 75 (61%) 
were males. They were followed up for a median of 
9.7 years (range, 0.2-27.6 years; including follow-up 
to adulthood). At the time of last follow-up near the 
time of the current study (August 2011), the median 
age of the 117 patients considered to be survivors 
was 16.2 years (range, 1.5-34.4 years), whereas six 
were known to have died.  Among the former 117 
patients,  18 lost to follow-up were regarded as alive 
(as at last follow-up). Most of the patients (80%) had 
participated in our NF1 surveillance programme for 
a median duration of 7.7 (range, 0.1-13.8) years, 12 of 
whom developed malignancies at a median age of 
13.6 (range, 0.8-41.6) years. There was no signiﬁcant 
difference in the proportions developing malignancy 
in males and females. The cumulative malignancy 
risk was estimated to be 12% at 20 years and 16% at 
30 years (Fig 1).
 Malignancies developed in patients with 
NF1 included: MPNST (n=3), neuroblastoma (n=1), 
rhabdomyosarcoma (n=1), osteosarcoma (n=1), optic 
nerve glioma (n=1), thalamic pilocytic astrocytoma 
* MRI denotes magnetic resonance imaging, VMA vanillylmandelic acid, HVA homovanillic acid, and CT computed tomography
TABLE 1.  The neuroﬁbromatosis type 1 surveillance programme*
Surveillance activities Start time Follow-up
History and clinical examination At diagnosis Every 6 to 12 months
MRI brain 5-6 Years old If normal, repeated once every 2 years, and at 17 years; 
if abnormal, repeated more frequently as indicated
MRI orbit and spine At diagnosis Repeated when indicated
Ultrasound abdomen At diagnosis Yearly (proceeding to CT or MRI if abnormal)
Blood counts and smear At diagnosis Alternate year
Urine VMA and HVA At diagnosis Alternate year
Skeletal survey At diagnosis None
Visual assessment by optometrist At diagnosis Yearly
Hearing assessment by audiologist At diagnosis Yearly
Intellectual assessment by clinical psychologist 6 Years old Repeated once 2 years later
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(n=1), juvenile myelomonocytic leukaemia (JMML) 
(n=2), anaplastic large cell lymphoma (ALCL) [n=1], 
and breast carcinoma and subsequently carcinoma 
of the ampulla of Vater (n=1). Patient characteristics, 
management, and outcomes are shown in Table 2.
 In three of the patients, malignancies (optic 
glioma, thalamic astrocytoma, sacral MPNST) were 
initially detected by surveillance using magnetic 
resonance imaging (MRI). The patient with 
rhabdomyosarcoma was diagnosed at a young age 
before surveillance was started. The patient with 
osteosarcoma presented with symptoms before 
the next scheduled follow-up. The patient with 
lymphoma was diagnosed in adulthood after leaving 
our surveillance programme. The remaining six 
patients never underwent surveillance. 
* JMML denotes juvenile myelomonocytic leukaemia, MPNST malignant peripheral nerve sheath tumour, and MRI magnetic resonance imaging
TABLE 2.  Characteristics of neuroﬁbromatosis type 1 patients with malignancies*
Pa-
tient 
No.
Type of 
malignancy
Sex Age at 
diagnosis of 
malignancy 
(years)
Presentation Joined 
sur-
veillance 
pro-
gramme
Malignancy 
picked 
up by 
surveillance 
or not
Treatment Outcome
1 JMML M 0.8 Fever for 3 days, 
hepatomegaly, 
splenomegaly, 
leukocytosis, 
monocytosis
No No Splenectomy, 
unrelated cord blood 
transplant
Relapsed at 4.9 years, 
on palliative care at last 
follow-up at 5.1 years
2 Neuroblastoma 
stage 4
M 1.58 Left supraclavicular 
lymphadenopathy, 
hepatomegaly
No No Chemotherapy, 
radiotherapy, 
autologous stem cell 
transplant
Relapsed at 2.5 years 
and died of progressive 
disease at 3.3 years
3 Presacral 
embryonal 
rhabdomyosarcoma
F 5.7 Left hip and buttock 
pain for 2 weeks
Yes No Surgical resection, 
chemotherapy, 
radiotherapy
Alive without disease at 
12.1 years
4 JMML M 9.4 Skin rash and fever No No Matched sibling 
bone marrow 
transplant
Relapsed at 9.9 years 
and died of progressive 
disease at 10.7 years
5 Sacral MPNST F 11.4 Tumour detected by 
surveillance MRI
Yes Yes Surgical resection Relapsed at 11.7 years 
and defaulted follow-up
6 Optic nerve glioma M 12.4 Tumour detected by 
surveillance MRI
Yes Yes No treatment Alive with non-progressive 
disease at 21.4 years
7 Thalamic pilocytic 
astrocytoma
F 14.9 Tumour detected by 
surveillance MRI
Yes Yes Partial surgical 
resection
Alive with non-progressive 
disease at 18.2 years
8 Cervical MPNST M 16.1 Left cervical mass No No Surgical resection, 
radiotherapy
Relapsed at 16.6 years, 
on palliative care at last 
follow-up at 17.4 years
9 Metastatic pelvic 
MPNST
F 16.6 Bilateral lower limb pain 
and numbness
No No Chemotherapy, 
radiotherapy
Died of progressive 
disease at 16.9 years
10 Telangiectatic 
osteosarcoma of 
distal femur 
M 17.3 Right knee pain for 2 
months
Yes No Surgical resection 
with reconstruction, 
chemotherapy
Alive without disease at 
21.3 years
11 Anaplastic large cell 
lymphoma
M 21.0 Bilateral cervical lymph 
node enlargement for 1 
month
Yes No Chemotherapy Relapsed at 23.0 years 
and died at 23.2 years
12 Carcinoma of 
breast
F 41.6 Left breast lump No No Mastectomy, 
radiotherapy, 
chemotherapy
Complete remission, 
subsequent carcinoma of 
Ampulla of Vater at 54.5 
years, relapsed and died 
at 56.2 years
FIG 1.  Cumulative malignancy risk in patients with 
neuroﬁbromatosis type 1 over time
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 Two of the 12 patients with malignancies 
(rhabdomyosarcoma and osteosarcoma) achieved 
long-term remission after multi-modality therapy 
that included surgery, and multi-agent chemotherapy 
with or without radiotherapy. The patient with 
an optic glioma received no treatment as he was 
asymptomatic, but he was actively monitored. The 
patient with a thalamic pilocytic astrocytoma had it 
partially resected and had non-progressive disease 
thereafter. The patient with a sacral MPNST underwent 
surgical resection only, and refused further adjuvant 
therapy. The tumour recurred for which he sought 
alternative treatment and defaulted follow-up. The 
patient with a cervical MPNST had disease relapse 
after surgical resection and radiotherapy. He had 
extensive disease and received palliative care. The 
patient with a metastatic MPNST had progressive 
disease despite chemotherapy and radiotherapy, 
and died 3 months after the diagnosis at the age 
of 16.9 years. One patient with JMML underwent 
a splenectomy followed by unrelated donor 
haematopoietic stem cell transplantation (HSCT). 
His disease recurred and he is currently receiving 
palliative care. The other patient with JMML relapsed 
3 months after a matched sibling bone marrow 
transplant and died of progressive disease at the age 
of 10.7 years. The patient with stage-4 neuroblastoma 
achieved remission after chemotherapy, radiotherapy 
and autologous peripheral blood stem cell 
transplantation, but relapsed 3 months later and died 
of progressive disease aged 3.3 years. The patient 
with ALCL achieved remission after chemotherapy 
but died with relapsed lymphoma 2 years later at 
the age of 23 years. The patient with breast cancer 
entered remission following surgery, radiotherapy 
and chemotherapy but developed carcinoma of 
ampulla of Vater about 13 years later. After resection, 
her carcinoma recurred with multiple metastases 
and she died at the age of 56 years. The 5-year overall 
survival and event-free survival in our NF1 patients 
with malignancies were 62% and 38%, respectively 
(Fig 2). 
 One patient with NF1 but without malignancy 
died at the age of 25 years, because of severe 
scoliosis causing severe restrictive lung disease 
and pneumonia. The overall 30-year survival of 
NF1 patients with or without malignancies differed 
signiﬁcantly (35% vs 93%, P<0.001) [Fig 3].
Discussion
To the best of our knowledge, this is the largest study 
on the spectrum of malignancies in Chinese patients 
with NF1, which is one of the cancer-predisposing 
genetic disorders. In epidemiological studies in 
Sweden and Denmark, the risk of malignancy in 
NF1 was estimated to be about 4 times that of the 
general population.5,16 The frequency of malignancy 
in NF1 in the UK was reported to be 7% by the age of 
20 years and 20% by the age of 50 years, which is in 
excess of that in the general population.4 We could 
not reliably estimate the frequency of malignancy 
in Chinese patients with NF1, owing to their 
geographical mobility, bias due to selective referral 
of malignant cases, and incomplete follow-up into 
older adulthood. 
 The distribution of different types of malig-
nancies in patients with NF1 is somewhat different 
among different populations. In Sweden and 
Denmark, carcinoma is the most common, followed 
by sarcoma16 or brain tumours.5 In the UK by contrast, 
the most common were connective tissue tumours, 
followed by brain tumours. The majority of the 
malignant connective tissue tumours were derived 
from neural-associated tissues (neuroﬁbrosarcoma, 
malignant neurilemmoma, spindle cell sarcoma of 
peripheral nerves, and MPNST), and brain tumours 
that mainly consisted of optic pathway gliomas.4 A 
smaller cohort in Pittsburgh demonstrated a similar 
pattern of malignancies, with brain tumours being 
the most common, followed by sarcoma of neural 
FIG 2.  Survival of patients with neuroﬁbromatosis type 1 with 
malignancy
FIG 3.  Overall survival of patients with and without 
neuroﬁbromatosis type 1
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origin.19 This pattern of malignancies was similar to 
what we found in our NF1 patients, and included a 
variety of many different malignancies. Females with 
NF1 were reported to be at higher risk of breast 
cancer than in the general population, particularly 
among those aged 40 to 50 years4 (like our patient). 
Multiple primary tumours were also quite common, 
and were reported in about 8% of NF1 patients with 
malignancy in the UK.4 Our cohort also showed a 
similar frequency of second primary tumours, one 
of 12 of whom had more than one primary tumour. 
Some studies reported that females had a higher risk 
of malignancy than males,4 but we did not replicate 
this observation, which may have been due to our 
relatively small sample size limiting the statistical 
power to detect a difference.
 In general, the treatment of malignancies in 
NF1 patients is similar to that in patients without 
NF1. The prognosis is variable and depends mainly 
on the histological type and treatment response. 
Patients with brain tumours tend to have better 
outcomes compared to their counterparts without 
NF1.20 Optic pathway gliomas in patients with NF1 
tend to occur within the ﬁrst 5 years of life and 
are also less likely to cause visual impairment than 
their sporadic counterparts.21 In NF1 patients, these 
tumours are usually stable for many years or only 
progress slowly22,23; some may even regress without 
speciﬁc treatment.24,25 In our study, both the patients 
with low-grade gliomas also demonstrated a non-
progressive course. When treatment is required due 
to progressive symptoms or complications (such as 
hydrocephalus) in this era, chemotherapy with or 
without surgical resection is usually the treatment of 
choice.22 Radiotherapy is not recommended owing to 
the heightened risk of second malignancies in these 
genetically susceptible subjects.22,26
 By contrast, NF1 patients with MPNST have 
signiﬁcantly poorer 5-year survival (0-21% only), 
compared to 42 to 54% for sporadic MPNST.17,18 
Sporadic MPNST mainly manifests in the elderly 
at a median age of 62 years.17 In patients with NF1, 
this tumour presents at a median age of 26 years.17 
Because of the young age of onset and poor 
associated survival, the life expectancy of such NF1 
patients is signiﬁcantly shorter; an average reduction 
of about 15 years has been reported.27,28 Whether this 
also applies to Chinese patients needs resolving by 
further follow-up of our patients. The high frequency 
coupled with the poor prognosis of MPNST and 
other malignancies in NF1 sufferers confers a poor 
outlook in these patients. This was also illustrated 
in the present study, in that patients who developed 
malignancies had signiﬁcantly worse overall survival, 
which was consistent with other studies,27,28 showing 
that  malignancies were the major cause.
 Whilst JMML is relatively infrequent in 
patients with NF1, it co-exists in about 11% of all 
cases.29 Allogeneic HSCT is the treatment of choice 
and should be performed early if a suitable human 
leukocyte antigen–matched donor is available.30 
In NF1 patients, the prognosis of JMML does not 
differ from most other cases with different causes 
of RAS signalling pathway dysregulation,30,31 and 
may be better than in those harbouring PTPN11 
mutations.31 Both patients with JMML in our cohort 
also underwent allogeneic HSCT but their disease 
recurred and their outcomes were dismal. 
 Whether malignancy surveillance in patients 
with NF1 is beneﬁcial remains controversial. In 
our NF1 surveillance programme, we perform 
biannual blood counts and urine vanillylmandelic 
acid and homovanillic acid, and annual abdominal 
ultrasonography and optometrist assessments to 
monitor for leukaemia, neuroblastomas, other intra-
abdominal tumours, and optic pathway gliomas. To 
screen for abnormalities, we also performed MRIs of 
the brain (twice) and of the orbit and spine (once). 
One study reported the usefulness of repeat MRIs,32 
while others disagreed.33 In the current study, three of 
the 12 malignancies were discovered by surveillance 
imaging. In two patients, they developed earlier than 
the start of surveillance and in another the malignancy 
developed in adulthood after he left our surveillance 
programme. Five patients developed malignancies in 
the era before we started surveillance. Interestingly, 
one developed a malignancy that presented between 
surveillance visits. These observations suggested that 
to detect malignancies earlier in patients with NF1, 
we have to start monitoring earlier, continuously, 
more frequently, and throughout most of adulthood. 
Whether such surveillance is effective in improving 
prognosis or cost-effective is questionable, especially 
if regular MRI has to be incorporated. Screening for 
optic pathway glioma by MRI may be a more reason- 
able option, as this tumour occurs in early childhood 
and screening can cease after the child is 6 years old. 
Moreover, in these patients the prevalence of such 
gliomas is high and effective treatment is available to 
prevent/limit visual impairment. Both patients with 
an optic pathway glioma in our cohort were detected 
by MRI, which enabled early treatment. Besides optic 
pathway gliomas, NF1 patients continue to have 
other co-morbidities, including but not limited to 
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follow-ups. In the primary care setting, physicians 
should be alert to common presentations of different 
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